%0 Journal Article
%T 靶向胶质母细胞瘤中的复制应激<br>Targeting the Replication Stress of Glioblastoma
%A 陈佳敏
%A 吴亮
%J World Journal of Cancer Research
%P 42-51
%@ 2164-9057
%D 2022
%I Hans Publishing
%R 10.12677/WJCR.2022.122006
%X 胶质母细胞瘤是成人常见的原发性脑肿瘤，病程短，预后差，具有极强的治疗抗性，目前临床治疗仍然以手术切除辅以放化疗为主。近期，新兴的电场疗法被加入到胶质母细胞瘤的辅助疗法中，其是否有效尚存在争议。在过去50年里，胶质母细胞瘤的药物研发停滞不前，临床急需有效的药物改善患者预后。早期研究表明，由于DDR通路的异常上调，GBM (Glioblastoma)是一种先天耐受放化疗的肿瘤。基于现有治疗GBM的方法均会造成DNA损伤的特点，抑制DDR通路激活，加剧复制应激可能是改善GBM患者预后的有效策略。因此，我们对目前GBM的治疗概况以及靶向GBM中的DDR通路，增强现有DNA损伤疗法的相关研究进展进行了综述。<br />
Glioblastoma is a common primary brain tumor among adults with a short course of disease, poor prognosis and elevated treatment resistance. Currently, clinical treatment of GBM is still based on surgical resection supplemented by radiotherapy and chemotherapy. Recently, the emerging tumor-treating fields (TTFs) therapy has been approved to treat GBM as adjuvant therapy, and its effectiveness is still controversial. In the past 50 years, drug development for glioblastoma has stagnated, and there is an urgent need for new drug to improve the outcomes of GBM patient. Early studies have shown that GBM is innately resistant to chemotherapy and radiotherapy due to abnormal upregulation of the DDR pathway. Therefore, based on the characteristics of existing therapies which cause DNA damage to inhibit tumor growth, we reviewed the current treatment of GBM and the related research progress of targeting the DDR pathway in GBM to enhance existing DNA damage therapies.
%K 胶质母细胞瘤，替莫唑胺，复制应激，DNA损伤反应，合成致死<br>Glioblastoma
%K TMZ
%K Replication Stress
%K DNA Damage Response
%K Synthetic Lethality
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=50030